Abstract: Methods and devices related to the treatment of diseases using phototherapy are described. Some embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising Ring System 1, Ring System 2, Ring System 3, Ring System 4 or Ring System 5. Methods of treating disease with phototherapy are also described.

Abstract: Methods and devices related to the treatment of diseases using phototherapy are described. Some embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising Ring System 1, Ring System 2, Ring System 3, Ring System 4 or Ring System 5. Methods of treating disease with phototherapy are also described.

Abstract: Methods and devices related to the treatment of diseases using phototherapy are described. Some embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising a compound of Formula 1. Methods of treating disease diseases with phototherapy are also described.

Abstract: Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell.

Abstract: Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell.

Abstract: Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell.

Abstract: Disclosed herein are compounds represented by a formula: R1—Ar1—X—Ar2—Ar3-Het, wherein R1, Ar1, X, Ar2, Ar3, and Het are described herein. Compositions and light-emitting devices related thereto are also disclosed.

Abstract: Methods and devices related to the treatment of diseases using phototherapy are described. Some embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising a compound of Formula 1. Methods of treating disease diseases with phototherapy are also described.

Abstract: Some embodiments provide a compound represented by Formula 1. Other embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising a compound of Formula 1. Other embodiments provide an organic light-emitting device optionally comprising a wavelength convertor. Methods related to the treatment of diseases using phototherapy area also described.

Abstract: Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incretin hormone activity are administered transepithelially using a transepithelial carrier peptide. The transepithelial peptide contains sufficient amino, guanidine or amidino groups to stimulate transepithelial delivery. In some embodiments, the transepithelial carrier and the peptide with incretin hormone activity are embedded in a pressure sensitive adhesive layer of a plaster or patch.

Abstract: Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incretin hormone activity are administered transepithelially using a transepithelial carrier peptide. The transepithelial peptide contains sufficient amino, guanidine or amidino groups to stimulate transepithelial delivery. In some embodiments, the transepithelial carrier and the peptide with incretin hormone activity are embedded in a pressure sensitive adhesive layer of a plaster or patch.

Abstract: The present invention provides a method for obtaining an aptamer capable of specifically adsorbing to Verotoxin-1 produced by Enterohemorrhagic Escherichia coli by an in vitro selection method utilizing affinity chromatography, particularly, a method including use of an affinity column immobilizing thereon a peptide having an amino acid sequence of Verotoxin-1, for the affinity chromatography, and a single strand nucleic acid molecule, which is an aptamer capable of specifically adsorbing to Verotoxin-1.

Abstract: The present invention provides an aptamer capable of specifically adsorbing to bisphenol A suspected to be an endocrine disrupter as a target molecule, a method for obtaining an aptamer capable of specifically adsorbing to bisphenol A by an in vitro selection method utilizing affinity chromatography using a carrier immobilizing bisphenol A, particularly, a method including use of an antagonistic elution buffer containing an amphiprotic organic solvent for elution by the affinity chromatography, and a single-strand nucleic acid molecule which is an aptamer obtained thereby.

Abstract: The present invention relates to an immunological detection method capable of performing detection of an analyte in a test sample, and a kit used therefor. There is provided an immunological detection method for detecting an analyte by using a water-absorbent substrate in which a capture region is positioned in a given region on a surface thereof, the capture region being immobilized with a first immunochemical component capable of specifically binding to the analyte, wherein the detection signal is amplified and a kit used therefor.

Abstract: The present invention provides a method for obtaining an aptamer capable of specifically adsorbing to Verotoxin-1 produced by Enterohemorrhagic Escherichia coli by an in vitro selection method utilizing affinity chromatography, particularly, a method including use of an affinity column immobilizing thereon a peptide having an amino acid sequence of Verotoxin-1, for the affinity chromatography, and a single strand nucleic acid molecule, which is an aptamer capable of specifically adsorbing to Verotoxin-1.

Abstract: The present invention provides an aptamer capable of specifically adsorbing to bisphenol A suspected to be an endocrine disrupter as a target molecule, a method for obtaining an aptamer capable of specifically adsorbing to bisphenol A by an in vitro selection method utilizing affinity chromatography using a carrier immobilizing bisphenol A, particularly, a method including use of an antagonistic elution buffer containing an amphiprotic organic solvent for elution by the affinity chromatography, and a single-strand nucleic acid molecule which is an aptamer obtained thereby.

Abstract: An immunoassay method comprising bringing an immobilized phase comprising, at different positions on a water-absorbable base material, at least two first immunity substances capable of specifically binding with at least two kinds of assay target substances selected from the group consisting of verotoxin-producing Escherichia coli, verotoxin and human hemoglobin contained in a test sample, into contact with a test sample and a liquid containing labeled immunity substances each comprising a second immunity substance that is labeled with colored particles and capable of binding with said assay target substance, thereby to form an assay target substance-labeled immunity substance complex and to bind said complex with respective first immunity substances at the immobilized phase.

Abstract: An immunoassay method comprising bringing an immobilized phase comprising, at different positions on a water-absorbable base material, at least two first immunity substances capable of specifically binding with at least two kinds of assay target substances selected from the group consisting of verotoxin-producing Escherichia coli, verotoxin and human hemoglobin contained in a test sample, into contact with a test sample and a liquid containing labeled immunity substances each comprising a second immunity substance that is labeled with colored particles and capable of binding with said assay target substance, thereby to form an assay target substance-labeled immunity substance complex and to bind said complex with respective first immunity substances at the immobilized phase.

Abstract: An immunoassay method comprising bringing an immobilized phase comprising, at different positions on a water-absorbable base material, at least two first immunity substances capable of specifically binding with at least two kinds of assay target substances selected from the group consisting of verotoxin-producing Escherichia coli, verotoxin and human hemoglobin contained in a test sample, into contact with a test sample and a liquid containing labeled immunity substances each comprising a second immunity substance that is labeled with colored particles and capable of binding with said assay target substance, thereby to form an assay target substance-labeled immunity substance complex and to bind said complex with respective first immunity substances at the immobilized phase.